This finding is consistent with that of our previous study that demonstrated that activation of the PI3K/AKT signaling pathway was responsible for the acquired resistance to sorafenib and that inhibition of AKT reversed the resistance in HCC [20–23]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.